Kornimate/medical-research-clean huggingface dataset:
detection of barrett s esophagus in patients without gerd symptoms

Conditions: Barrett's Esophagus

Summary: the purpose of this study is to develop a method to detect barrett's esophagus (be) in individuals with a new office-based diagnostic test.

this study will investigate whether using esocheck/esoguard(ec/eg) can detect be in individuals at risk for be who are currently not being detected and are not undergoing routine esophago-gastro-duodenoscopy (egd) be can only be diagnosed by performing upper endoscopy. up to 500 adults who have risk factors for be but do not have chronic heartburn or regurgitation will be enrolled in this study. this will include the esocheck/esoguard determination along with the upper endoscopy for qualifying esoguard negative subjects

Eligibility criteria:
inclusion criteria: * no known coagulopathy, no known esophageal varices. * no significant dysphagia or odynophagia * absence of chronic gerd, defined as five or more years of heartburn or regurgitation with symptoms at least once a week when not on medications for gerd symptoms. * subjects to qualify must meet criterion 3, be over age 50, and have two additional risk factors for be (white race, central obesity defined as waist size \>35 inches for women and \>40 inches for men, male gender, current smoker or smoking history \>10 pack years, confirmed family history in at least two members with one being a first degree relative). exclusion criteria: * history of prior egd procedure * inability to provide written informed consent * history of weekly of more frequent heartburn or regurgitation for five or more years * on anti-coagulant drug(s)that cannot be temporarily discontinued or coagulopathy with international normalized ratio (inr) \> 1.5 * known history of esophageal varices or esophageal stricture * any contraindication, as deemed ininvestigator's medical judgment, to undergoing the esocheck procedure, undergoing the egdprocedure,and/or having biopsies taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula and/or esophageal ulceration * history of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills * oropharyngeal tumor * history of esophageal or gastric surgery, with exception on uncomplicated surgical fundoplication procedure * history of myocardial infarction or cerebrovascular accident within past 6 months
evaluation of transdermal nicotine replacement therapy (nrt) activity through metabolic induction

Conditions: Smoking; Addiction

Summary: evaluation to determine if auto-induction can be used as a surrogate measure of nicotine receptor up-regulation through an observational study using nicotine replacement therapy for two weeks and no intervention for two weeks.

studies have shown that prolonged exposure to nicotine reinforces addiction. the act of smoking delivers nicotine through lungs into the blood stream. as a result, during smoking nicotine levels peak and then when smoking stops levels progressively diminish to a base (trough) level. at the peak level a smoker feels rewarded, but at the trough level a smoker starts to experience negative withdrawal affects and a desire to smoke. nicotine gum and inhalers mimic this smoking behaviour maintaining a peak and trough regime, but nicotine patches do not. instead, nicotine patches deliver a constant base dose considered to be either above that of the smokers trough level or at a level where negative withdrawal effects are reduced. the question arises as to if nicotine levels delivered by a patch are constant and potentially above that of the baseline smokers level, does this reinforce the addiction and therefore contribute to the high long term relapse rate? to answer this question the investigators will be looking at metabolites which the body uses to breakdown nicotine and several other enzymes. these metabolites respond to the levels of nicotine in the blood stream by increasing or decreasing over time. by testing blood flow, blood and urine the investigators are able to gain an insight into how the body is dealing with a constant stable dose of nicotine rather than a peak and trough dose. in combination with the questionnaires the investigators will be able to determine the level of affect.

Eligibility criteria:
inclusion criteria: * smokers who currently smoke at least 10 cigarettes per day * aged between 18 and 75 * informed consent * willingness to attempt to quit smoking for the period specified, initially with a transdermal patch for 14 days and then without any smoking cessation aids for a further 14 days. exclusion criteria: * use of bupropion, champix or nicotine containing products other than cigarettes in the last 2 months * previous reactions to nrt * pregnancy / breast feeding * uncontrolled hypertension * unstable angina * heart attack or stroke within the previous 6 months * severe obesity as indicated by body mass index (bmi) ≥35 (potential for slow release of nicotine from tissues) * acute psychiatric illness, past history psychosis, suicidal ideation or current diminished capacity. * current treatment or recent diagnosis of cancer * current use of phenobarbital or other anticonvulsant drugs (induction of metabolism of nicotine to cotinine) * renal failure (creatinine clearance\<30ml/min - reduces metabolic clearance of cotinine and nicotine)

Keywords: nrt patch smoking addiction
follow-up study after aclsct for restoration of corneal epithelium in patients with lscd due to ocular burns

Conditions: Limbal Stem Cell Deficiency Due to Ocular Burn

Summary: this is a multinational, multicentre, prospective, non-pharmacological follow-up study of the clinical trial holocore. all patients transplanted with holoclar in the holocore clinical trial who consent to participate will be enrolled in this prospective study and observed for at least 12 months.

holocore follow-up prospective study offers the opportunity to collect long-term efficacy and safety data after one or two treatments with holoclar. moreover, since holoclar (study drug used in the main holocore interventional clinical trial) is suspected to improve the success of keratoplasty in those patients candidate to receive this treatment but no data were collected in the three previous retrospective studies (hlstm01, hlstm02 and hlstm04) on holoclar, this follow-up study has been thought to observe the progress of the disease and to collect data on keratoplasty and evaluate the benefits of holoclar in subsequent keratoplasty in patients treated once or two times with holoclar. all patients treated in the holocore clinical trial who consent to roll over to the present extension study at the end of the holocore will be observed for a follow-up period which may vary from a minimum of 12 month for the last patient to a maximum of 57 months for the first patient entered. a total of approximately 70 patients is expected (all patients who completed the holocore study). in case the last enrolled patient undergoes to keratoplasty at the last visit of the follow-up study, this will consequently lead to a prolongation of the study up to further 12 months for all patients. the subjects will be enrolled and observed at the same investigational centers where they were recruited for the holocore clinical trial. no drug will be administered for the scope of this study. ophtalmological visits including pictures collection and quality of life evaluations will be performed every 6 months.

Eligibility criteria:
inclusion criteria: * all patients (adults and pediatrics) who completed the holocore core study and who consent to roll over to the present extension study at the end of the holocore follow-up. exclusion criteria: * no specific exclusion criterion is considered for this study, except for patients dropping out from the holocore study or withdrawing consent.

Keywords: lscd, holoclar, follow-up
efficacy of retrograde fill vs spontaneous fill to assess voiding function

Conditions: Urinary Retention; Surgery

Summary: purpose: the purpose of this study is to determine if two different methods of performing a postoperative voiding trial are equivalent in evaluating urinary retention after gynecologic surgery. participants: the participants in this study will be women who have undergone gynecologic surgery at unc-chapel hill.

subjects will be enrolled in the study when presenting to the unc gynecology outpatient clinic for surgical preoperative evaluation. after surgery, each woman will undergo a voiding trial to assess for urinary retention after surgery. this is currently performed on all patients undergoing surgery involving prolapse or incontinence. at unc this is usually performed by allowing the bladder to spontaneously fill, then allowing the patient to void and afterward catheterizing the patient to check a postvoid residual ("spontaneous fill" technique). in this study, we will also assess bladder emptying separately by filling the bladder retrograde through the catheter already in place with 300 ml of saline and then removing the catheter and allowing the patient to void ("retrograde-fill" technique). we will determine postvoid residual indirectly by subtracting voided volume from the 300 ml infused volume. no catheterization will be performed with this technique. both of these techniques will be performed. the order in which the two techniques will be performed will be randomized. we will then compare the outcomes of these two techniques of voiding trials to see if they are equivalent in assessing urinary retention. of note, the retrograde fill technique is standard at other institutions and is not considered experimental.

Eligibility criteria:
inclusion criteria: 1. women undergoing surgical correction of pelvic organ prolapse or urinary incontinence exclusion criteria: 1. unwillingness to participate in the investigation. 2. inability to give informed consent. 3. known preoperative voiding dysfunction 4. plan for suprapubic catheter placement at time of surgery. 5. age less than 18 6. non-english speaking

Keywords: voiding trial, urinary retention, catheterization urinary retention after gynecologic surgery
nutrition tubes on sleep quality in stroke-related dysphagia

Conditions: Dysphagia

Summary: palliation to stroke-related dysphagia continues to be a challenge. although nasogastric tube feeding (ngt) has been adopted widely, the weaknesses have yet to be improved by another enteral nutrition support mode. this study aims to observe the clinical efficacy of intermittent oro-esophageal tube feeding (ioe) in the treatment of stroke-related dysphagia on sleep quality. this is a prospective study with patients with dysphagia after stroke. patients enrolled are randomly divided equally into 2 groups. all patients receive conventional care, and the observation group received ioe while the control group received ngt for enteral nutrition support. their sleep quality are compared at baseline and after study.

this study lasts 15 days for each patient. palliation to stroke-related dysphagia continues to be a challenge. although nasogastric tube feeding (ngt) has been adopted widely, the weaknesses have yet to be improved by another enteral nutrition support mode. this study aims to observe the clinical efficacy of intermittent oro-esophageal tube feeding (ioe) in the treatment of stroke-related dysphagia on sleep quality. this is a prospective study with patients with dysphagia after stroke. patients enrolled are randomly divided equally into 2 groups. all patients receive conventional care, and the observation group received ioe while the control group received ngt for enteral nutrition support. their sleep quality are compared at baseline and after study.

Eligibility criteria:
inclusion criteria: * age\>18 years. * meeting the diagnostic criteria for ischemic stroke . * dysphagia confirmed by videofluoroscopic swallowing study. * clear consciousness. * no history of prior stroke. * stable vital signs. exclusion criteria: * dysphagia that might be caused by other diseases that might cause dysphagia, such as head and neck tumors, traumatic brain injury, myasthenia gravis, etc. * complicated with severe liver and kidney failure, tumors, or hematological disorders. * simultaneously in need to undergo other therapy that might affect the outcomes of this study. * pregnant or nursing females.
cross cultural adaptation, validity and reliability test of the arabic version of the outpatient physical therapy improvement in movement assessment log

Conditions: Physical Performance; Outpatients

Summary: purpose of the study: to translate, culturally adapt, and to test the validity and reliability of the outpatient physical therapy improvement in movement assessment log in arabic speaking language.

the optimal assessment log was produced in english and later on it was being validated into italian and spanish versions. it hasn't been produced into arabic yet so the aim of this study is to test the validity , reliability and psychometric properties of this assessment tool when being translated into arabic and used among the arabic egyptian people.

Eligibility criteria:
inclusion criteria: 1. participants are adult outpatients who took at least a month of physiotherapy sessions. 2. both genders will be included. 3. at least 18 years of age. 4. participants must be conscious and ambulant. 5. participants able to read, write arabic as a mother tongue and understand the instructions, questions in the questionnaire. exclusion criteria: participants having the following conditions will be excluded from the study: 1. patients who are not able to provide informed consent. 2. patients who are unable to complete the optimal instrument. 3. patients who have a severe cognitive impairment. 4. patients who are not receiving physical therapy. 5. patients who are not arabic-speaking. 6. patients who have a history of malingering

Keywords: questionnaire optimal validity testing arabic version psychometric properties reliability testing
the effects of beta-glucan enriched oatcake consumption on metabolic disease risk factors

Conditions: Metabolic Syndrome X; Cardiovascular Diseases

Summary: the purpose of this study is to determine whether daily consumption of soluble fibre, oat beta glucan (4g), for six weeks will have any impact on overweight/obese individuals in terms of risk factors used to define metabolic disease.

the purpose of this study is to determine whether daily consumption oat beta glucan (4g) for six weeks will have any impact on overweight/obese individuals in terms of risk factors used to define metabolic disease. oat beta-glucan has been incorporated into a novel oatcake product manufactured by nairn's oatcakes ltd. consumption of the oatcake products will deliver enough oat-beta glucan to the diet to meet european food safety authority health claims for lowering blood cholesterol and reducing post-prandial glycaemic responses.

Eligibility criteria:
inclusion criteria: * males and females 18 years and older * waist circumference measurements of ≥94cm for males and 80cm for females, or a body mass index of ≥30kg/m2 * individuals who are able to provide informed consent exclusion criteria: * postmenopausal females * smokers * individuals who suffer from, or taking medication for, cardiovascular or gastro-intestinal disease * impaired glucose tolerance/diabetes mellitus * pregnancy or breastfeeding * those who have high dietary fibre intakes (\>20g/day) * known food allergies to oats, wheat, lactose, or sesame seeds

Keywords: metabolic syndrome x overweight waist circumference blood pressure cholesterol oat beta glucan
efficacy of acetaminophen-ibuprofen combination on the postoperative pain after laparoscopic gynecology surgery

Conditions: Gynecologic Disease

Summary: acetaminophen and ibuprofen has been safely used for a long time and reduces postoperative pain and opioid dosages. investigators are planning to compare the efficacy of 1) acetaminophen only and 2) acetaminophen and ibuprofen combination at postoperative pain after laparoscopic gynecologic surgery.

acetaminophen and ibuprofen has been safely used for a long time and reduces postoperative pain and opioid dosages. investigators are planning to compare the efficacy of 1) acetaminophen 1g only and 2) the combination of acetaminophen 1g and ibuprofen 300mg at postoperative pain after laparoscopic gynecologic surgery. some recovery valuables such as the postoperative pain and opioid requirements will be assessed.

Eligibility criteria:
inclusion criteria: * patients scheduled gynecologic laparoscopic surgery exclusion criteria: 1. refusal to be enrolled in the study 2. emergency surgery 3. on chronic pain medications 4. psychiatric disorders 5. pregnant, lactating women 6. allergy or contraindication to the medication drugs
synapse alterations in msa patients

Conditions: Multiple System Atrophy

Summary: synaptic loss has been implicated in various neurodegenerative conditions, yet its understanding in multiple system atrophy (msa) remains limited. the aim of this study was to examine spatial synaptic density alterations in msa patients and evaluate the potential of \[18f\]synvest-1 pet as an imaging biomarker for msa in both diagnosis and monitoring disease severity.

60 msa patients (30 msa-p subtype and 30 msa-c subtype) and 30 age-matched healthy controls (hcs) underwent \[18f\]synvest-1 pet/ct for synaptic density assessment. visual, voxel, and volumetric region-of-interest (voi) analyses were employed to elucidate synaptic density patterns in the msa brain and establish visual diagnostic criteria. voi-based computer-assisted analyses were utilized to develop diagnostic models for msa.

Eligibility criteria:
inclusion criteria: the msa patient were diagnosed according to the 2008 second consensus criteria and confirmed by two experienced neurologists. exclusion criteria: encompassed mri contraindications, a history of epilepsy, stroke, or brain surgery, intracranial organic lesions unrelated to msa, usage of levetiracetam or brivaracetam, and a history of alcohol or drug abuse

Keywords: synaptic density; pet; sv2a
treatment of pendular nystagmus with gabapentin and memantine in patients with multiple sclerosis

Conditions: Pendular Nystagmus Patients With Multiple Sclerosis

Summary: different treatment trials have been published in acquired nystagmus in the last decade; gabapentin and memantine have been found to be efficient in treating pendular nystagmus in multiple sclerosis. the effects of treatments are measured on nystagmus velocity, amplitude, frequency and on visual acuity. none of the trials measured a functional visual score or oscillopsia score. the aim of our study is to evaluate the effect of gabapentin and memantine on the mean velocity, amplitude and frequency of pendular nystagmus, as well as on oscillopsia, visual acuity and vision-specific health-related quality of life score, in 10 patients with multiple sclerosis. the primary object is to find out the best variable to evaluate the efficiency of nystagmus treatment and the secondary, to compare the efficiency of both gabapentin and memantine in a common population of patients.


Eligibility criteria:
inclusion criteria: * all patients may have a clinically definite, laboratory-supported diagnosis of multiple sclerosis according to the mac donald criteria. * all patients may present a chronic acquired pendular nystagmus due to ms, observed over a period of 6 months. * all patients will be informed about the design and purpose of the study, and all will give their informed, written consent to the protocol, which may have been approved by the local ethics committee. * age: above 18 * able to understand the instructions * having a health coverage * able to sit down for 1 hour * stable dosage of previous medications (beginning 3 weeks previously and terminating at the end of the trial duration), except for steroids, gabapentin or memantine. exclusion criteria: * ophthalmological * other ophthalmological disorder that could impair corrected visual acuity (maculopathy, retinopathy...) * neurological * ongoing seizure * severe handicap that does not allow sitting down position for 1 hour * suicidal behavior or risk * treatment * under memantine or gabapentin medication (these medications should have been stopped for at least 1 week for gabapentin and 3 weeks for memantine) * under morphine, n-methyl-d-aspartate such as amantadine, ketamine or dextromethorphan * steroid medication for a current relapse (beginning 3 weeks previously and terminating at the end of the trial duration) * known hypersensitivity to memantine or gabapentin * general * unstable medical state * patient with a galactose intolerance, a lapp lactase deficiency or glucose-galactose malabsorption * moderate renal failure (creatinine clearance \< 50 ml/min on bioassay dated from less than one month) * recent heart infarction (\<3months) * unstable congestive heart insufficiency * unstable arterial hypertension * leucopenia (\<2500/mm3) * transaminase increase (\>5 time normal values) * pregnancy (on questioning) * tutelage or any legal protection measure
evaluating simvastatin's potential role in therapy

Conditions: Alzheimer Disease

Summary: the purpose of this study is to see how simvastatin, a cholesterol-lowering drug, affects processes related to the development of alzheimer's disease, including: 1) levels of a substance called beta-amyloid-42 found in the spinal fluid surrounding the brain, 2) blood flow in the brain, 3) inflammation in the brain, and 4) cognitive function.

some studies suggest that statin medications, which are a group of cholesterol-lowering medicines, may help prevent alzheimer's disease. however, this has not been proven in humans. the purpose of this study is to see how simvastatin affects a substance in the spinal fluid around the brain called beta-amyloid-42 which is thought to contribute to alzheimer's disease. this study also evaluates whether simvastatin improves regional brain blood flow (on magnetic resonance imaging \[mri\]), reduces inflammation, and improves cognitive function. the esprit study was a 9-month randomized, controlled clinical trial that randomized 100 middle-aged adults with a parental history of alzheimer's disease. participants were randomized to simvastatin 40 mg for one month then 80 mg daily or matching placebo tablets. fifty of the esprit subjects participated in the mri sub-study. participants had the following data collected: fasting blood tests (baseline and months 3 and 9), medical history and medication questionnaires (each visit), study medication side effect review (all visits), lumbar puncture procedure (baseline and month 9), memory testing (baseline and months 3 and 9), and mri (baseline and month 9 in 50 sub-study participants).

Eligibility criteria:
inclusion criteria: * age 35 to 69 * parent with alzheimer's disease exclusion criteria: * current use of cholesterol-lowering medication * active liver disease * history of adverse reaction to statins * contraindication to lumbar puncture * elevated lab values (creatine kinase and creatinine) * use of medications known to interact with statins * history of dementia * currently pregnant or planning to become pregnant * use of large quantities of grapefruit juice (more than 1 quart per day) * current involvement in another investigational drug study * contraindications to mri (for mri sub-study) * ethical contraindication to placebo (persons with high vascular risk)

Keywords: amyloid protein apolipoprotein cerebrospinal fluid cerebrovascular circulation inflammation magnetic resonance imaging prevention & control